Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arcutis Biotherapeutics Inc
(NQ:
ARQT
)
10.88
-0.12 (-1.09%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcutis Biotherapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
12 Health Care Stocks Moving In Thursday's After-Market Session
October 19, 2023
Via
Benzinga
Arcutis Announces Proposed Public Offering
October 19, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2023
October 13, 2023
Via
Benzinga
Analyst Expectations for Arcutis Biotherapeutics's Future
October 13, 2023
Via
Benzinga
Where Arcutis Biotherapeutics Stands With Analysts
September 25, 2023
Via
Benzinga
Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
October 13, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11
October 06, 2023
Expanded indication for ZORYVE provides new, steroid-free topical for children 6 to 11 with plaque psoriasis, including intertriginous psoriasis
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Why Shares of Arcutis Biotherapeutics Fell This Week
September 07, 2023
The company released phase 3 trial results for an atopic dermatitis cream.
Via
The Motley Fool
7 Analysts Have This to Say About Arcutis Biotherapeutics
August 10, 2023
Via
Benzinga
8 Analysts Have This to Say About Arcutis Biotherapeutics
July 18, 2023
Via
Benzinga
Arcutis Appoints L. Todd Edwards as Chief Commercial Officer
September 27, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
September 26, 2023
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis
September 25, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Biotherapeutics Reveals Promising Data From Lead Drug In Pediatric Patients With Atopic Dermatitis
September 19, 2023
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) announced that the INTEGUMENT-PED Phase 3 trial of roflumilast cream 0.05%, in children ages 2 to 5 years with mild to moderate atopic dermatitis met its...
Via
Benzinga
Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
September 19, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older
September 12, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
US Stocks Mostly Higher; RH Posts Upbeat Earnings
September 08, 2023
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 60 points on Friday. Following the market opening Friday, the Dow traded down 0.03% to 34,491.98 while the NASDAQ...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)
September 07, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis to Present at Upcoming Investor Conference
September 05, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
3 Biotech Stocks Due for a Massive Short Squeeze
August 31, 2023
These are the biotech short squeeze candidates to buy and hold for a massive rally of up to 100% in the coming quarters.
Via
InvestorPlace
Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report
August 31, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%
August 29, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
August 21, 2023
Via
Benzinga
Why Super League Gaming Are Trading Lower By Around 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session
August 21, 2023
Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) shares jumped 120% to $0.33.
Via
Benzinga
Week In Review: Hengrui Out-Licenses Novel Anti-Inflammatory To One Bio In $1 Billion Deal
August 19, 2023
Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for a novel anti-inflammatory to One Bio of Florida in a $1 billion deal. One Bio will make an $21.5 million payment upfront along with a...
Via
Talk Markets
Arcutis Appoints Interim Chief Financial Officer (CFO)
August 18, 2023
Former and First Arcutis CFO, John Smither, Appointed Interim
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
August 10, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis to Report Second Quarter Financial Results
July 24, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark
July 17, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.